Artivion, Inc. (NYSE:AORT) CFO Sells $89,003.29 in Stock

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the completion of the transaction, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. This represents a 4.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Stock Performance

NYSE:AORT opened at $25.44 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The business has a fifty day simple moving average of $29.68 and a two-hundred day simple moving average of $27.83. Artivion, Inc. has a 1 year low of $18.38 and a 1 year high of $32.33. The company has a market capitalization of $1.07 billion, a P/E ratio of -1,272.00 and a beta of 1.75.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. On average, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on AORT. Stifel Nicolaus dropped their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC decreased their price target on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Finally, Oppenheimer increased their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $31.40.

Hedge Funds Weigh In On Artivion

Large investors have recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after acquiring an additional 25,176 shares during the period. Barclays PLC boosted its holdings in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Artivion in the third quarter worth $5,798,000. JPMorgan Chase & Co. boosted its holdings in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after acquiring an additional 125,668 shares during the period. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.